KUALA LUMPUR, Oct 20 — Adagio Therapeutics Inc, a clinical-stage biopharmaceutical company has announced new in-vitro data demonstrating retained neutralising activity of its monoclonal antibody (mAb), ADG20, against a diverse panel of circulating SARS-CoV-2 variants, including the newly emerged Lambda and Mu variants.
Notably, findings show that ADG20 demonstrated potent in-vitro neutralising activity against all SARS-CoV-2 variants of concern tested, including those with reduced susceptibility to mAb products currently available under Emergency Use Authorization (EUA) or in late-stage development.
According to a statement, these data will be presented during a poster session at the 2021 ISIRV-WHO Virtual Conference, which is being held Oct 19-21.
In addition, Adagio will present an encore poster highlighting recently announced data from the company’s ongoing Phase 1 trial of ADG20 in healthy participants.
“These new variant data further underscore the potential of ADG20 to address the ongoing COVID-19 pandemic, as well as possible future outbreaks caused by other SARS-like viruses,” said co-founder and chief scientific officer of Adagio, Laura Walker, Ph.D.
“We have intentionally designed this mAb to have both broad and potent neutralising activity as well as a half-life that extends its potential window of protection, critical features that may set it apart from other therapies available under EUA or in development today.
“With global Phase 2/3 prevention and treatment trials ongoing, we look forward to continuing our evaluation of ADG20 to assess the meaningful role it could potentially play in the arsenal of COVID-19 treatment options.”
In addition to the Phase 1 healthy participant trial, Adagio is advancing two ongoing global Phase 2/3 trials with ADG20, a treatment trial (STAMP) and a prevention trial (EVADE).
The company anticipates submitting an EUA application to the U.S. Food and Drug Administration for ADG20 in the first quarter of 2022.
Source: BERNAMA News Agency